Abivax (ABVX) Retained Earnings (2022 - 2026)

Abivax's Retained Earnings history runs 5 years deep, the most recent figure standing at -$838.1 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 83.52% year-over-year to -$838.1 million; the TTM figure through Mar 2026 stood at -$838.1 million (down 83.52% YoY), while the FY2025 annual figure was -$468.4 million, down 66.89% from the prior year.
• Retained Earnings was -$838.1 million for Q1 2026 at Abivax, down from -$468.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$62.0 million in Q4 2022 to a low of -$838.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$390.4 million across 5 years, with a median of -$456.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings tumbled 134.75% in 2023, then plunged 65.66% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$62.0 million in 2022, then plunged by 134.75% to -$145.5 million in 2023, then plunged by 92.92% to -$280.7 million in 2024, then slumped by 66.89% to -$468.4 million in 2025, then slumped by 78.93% to -$838.1 million in 2026.
• The last three Retained Earnings figures came in at -$838.1 million (Q1 2026), -$468.4 million (Q4 2025), and -$485.9 million (Q3 2025), per Business Quant data.